S&P 500   3,390.76 (+0.61%)
DOW   29,382.10 (+0.51%)
QQQ   237.18 (+1.04%)
FB   217.85 (+0.02%)
MSFT   187.34 (+0.06%)
GOOGL   1,529.14 (+0.64%)
AMZN   2,179.85 (+1.12%)
NVDA   312.51 (+5.37%)
MU   59.62 (+3.24%)
GE   12.76 (+0.08%)
AMD   59.09 (+3.87%)
ACB   1.70 (+3.66%)
F   8.01 (-0.62%)
NFLX   388.29 (+0.13%)
BAC   34.79 (+1.52%)
DIS   141.17 (+1.46%)
GILD   67.14 (+0.18%)
S&P 500   3,390.76 (+0.61%)
DOW   29,382.10 (+0.51%)
QQQ   237.18 (+1.04%)
FB   217.85 (+0.02%)
MSFT   187.34 (+0.06%)
GOOGL   1,529.14 (+0.64%)
AMZN   2,179.85 (+1.12%)
NVDA   312.51 (+5.37%)
MU   59.62 (+3.24%)
GE   12.76 (+0.08%)
AMD   59.09 (+3.87%)
ACB   1.70 (+3.66%)
F   8.01 (-0.62%)
NFLX   388.29 (+0.13%)
BAC   34.79 (+1.52%)
DIS   141.17 (+1.46%)
GILD   67.14 (+0.18%)
S&P 500   3,390.76 (+0.61%)
DOW   29,382.10 (+0.51%)
QQQ   237.18 (+1.04%)
FB   217.85 (+0.02%)
MSFT   187.34 (+0.06%)
GOOGL   1,529.14 (+0.64%)
AMZN   2,179.85 (+1.12%)
NVDA   312.51 (+5.37%)
MU   59.62 (+3.24%)
GE   12.76 (+0.08%)
AMD   59.09 (+3.87%)
ACB   1.70 (+3.66%)
F   8.01 (-0.62%)
NFLX   388.29 (+0.13%)
BAC   34.79 (+1.52%)
DIS   141.17 (+1.46%)
GILD   67.14 (+0.18%)
S&P 500   3,390.76 (+0.61%)
DOW   29,382.10 (+0.51%)
QQQ   237.18 (+1.04%)
FB   217.85 (+0.02%)
MSFT   187.34 (+0.06%)
GOOGL   1,529.14 (+0.64%)
AMZN   2,179.85 (+1.12%)
NVDA   312.51 (+5.37%)
MU   59.62 (+3.24%)
GE   12.76 (+0.08%)
AMD   59.09 (+3.87%)
ACB   1.70 (+3.66%)
F   8.01 (-0.62%)
NFLX   388.29 (+0.13%)
BAC   34.79 (+1.52%)
DIS   141.17 (+1.46%)
GILD   67.14 (+0.18%)
Log in

NASDAQ:VERU - Veru Stock Price, Forecast & News

$4.23
-0.16 (-3.64 %)
(As of 02/19/2020 01:51 PM ET)
Today's Range
$4.23
Now: $4.23
$4.37
50-Day Range
$3.33
MA: $3.94
$4.56
52-Week Range
$1.18
Now: $4.23
$4.74
Volume3,338 shs
Average Volume428,854 shs
Market Capitalization$275.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. Read More…

Industry, Sector and Symbol

Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
Current SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.80 million
Book Value$0.45 per share

Profitability

Net Income$-12,020,000.00

Miscellaneous

Employees171
Market Cap$275.75 million
Next Earnings Date5/20/2020 (Estimated)
OptionableOptionable

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.


Veru (NASDAQ:VERU) Frequently Asked Questions

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) announced its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.03. The business earned $10.58 million during the quarter, compared to analysts' expectations of $9.30 million. Veru had a negative return on equity of 40.45% and a negative net margin of 36.58%. View Veru's Earnings History.

When is Veru's next earnings date?

Veru is scheduled to release their next quarterly earnings announcement on Wednesday, May 20th 2020. View Earnings Estimates for Veru.

What price target have analysts set for VERU?

5 Wall Street analysts have issued 12-month price objectives for Veru's shares. Their forecasts range from $5.00 to $12.00. On average, they expect Veru's share price to reach $6.80 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price. View Analyst Price Targets for Veru.

What is the consensus analysts' recommendation for Veru?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru.

Has Veru been receiving favorable news coverage?

Media coverage about VERU stock has trended somewhat negative on Wednesday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Veru earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Veru.

Are investors shorting Veru?

Veru saw a increase in short interest in January. As of January 31st, there was short interest totalling 238,900 shares, an increase of 109.0% from the January 15th total of 114,300 shares. Based on an average daily trading volume, of 306,600 shares, the short-interest ratio is presently 0.8 days. Approximately 0.5% of the shares of the stock are short sold. View Veru's Current Options Chain.

Who are some of Veru's key competitors?

What other stocks do shareholders of Veru own?

Who are Veru's key executives?

Veru's management team includes the folowing people:
  • Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)
  • Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)
  • Mr. O. B. Parrish, Co-Founder & Director (Age 86)
  • Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)
  • Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51)

Who are Veru's major shareholders?

Veru's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.39%), EAM Investors LLC (0.46%), Wedge Capital Management L L P NC (0.45%), Credit Suisse AG (0.17%), Raymond James & Associates (0.14%) and Goldman Sachs Group Inc. (0.04%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View Institutional Ownership Trends for Veru.

Which institutional investors are selling Veru stock?

VERU stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates and UBS Group AG. View Insider Buying and Selling for Veru.

Which institutional investors are buying Veru stock?

VERU stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, EAM Investors LLC, Credit Suisse AG, Wedge Capital Management L L P NC, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Alpine Global Management LLC and Alambic Investment Management L.P.. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View Insider Buying and Selling for Veru.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $4.26.

How big of a company is Veru?

Veru has a market capitalization of $277.71 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe.View Additional Information About Veru.

What is Veru's official website?

The official website for Veru is http://www.veruhealthcare.com/.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]


MarketBeat Community Rating for Veru (NASDAQ VERU)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel